CytRx to Participate in Upcoming Investor Conferences

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to participate in the following upcoming conferences:

• H.C. Wainwright Global Life Sciences Conference: March 9-10, 2021
  • Mr. Kriegsman will deliver a virtual presentation that will be available to conference participants on-demand beginning March 9, 2021.

• Virtual 33^rd Annual ROTH Conference: March 15-17, 2021
  • Mr. Kriegsman will deliver a virtual presentation that may be accessed on the News and Events page of the CytRx website beginning March 5, 2021.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is www.cytrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005178/en/